Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1100061 | 0.95 | FASN (0.45) | FASNRAB9ALMNACACNA1HL3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL1100995 | 0.93 | DGAT1 (0.44) | LMNADGAT1HTTMAPT | |
| Trifluoroacetic Acid SCHEMBL1101032 | 0.92 | DGAT1 (0.45) | DGAT1ALDH1A1MAPT | |
| Trifluoroacetic Acid SCHEMBL1101066 | 0.90 | FASN (0.42) | FASNLMNACACNA1HDGAT1TP53 | |
| Trifluoroacetic Acid SCHEMBL1100255 | 0.89 | KDM4E (0.43) | FASNLMNACACNA1HDGAT1ALDH1A1 | |
| SCHEMBL1099159 | 0.87 | DGAT1 (0.47) | FASNLMNADGAT1ALDH1A1TSHR | |
| SCHEMBL1100494 | 0.86 | CNR1 (0.49) | RAB9ACACNA1HDGAT1ALDH1A1 | |
| SCHEMBL1100786 | 0.86 | CNR1 (0.47) | RAB9AL3MBTL1DGAT1 | |
| SCHEMBL1100783 | 0.86 | L3MBTL1 (0.47) | FASNRAB9ACACNA1HL3MBTL1DGAT1 | |
| Trifluoroacetic Acid SCHEMBL1099895 | 0.86 | MAPT (0.44) | LMNAL3MBTL1DGAT1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716272-B2 | N-(amino-heteroaryI)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| US-8716273-B2 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| US-20120142669-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI-AVENTIS (FR) | 2012-06-07 | — | — | US | disclosed |
| US-20120142670-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI-AVENTIS (FR) | 2012-06-07 | — | — | US | disclosed |
| US-8153650-B2 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI-AVENTIS (FR) | 2012-04-10 | — | — | US | disclosed |
| US-20100041634-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142670-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | ZYX, NQO2, PYCR1 | FASN 1957/4885RAB9A 2711/4885LMNA 2507/4885 |
| US-20120142669-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | ZYX, NQO2, PYCR1 | FASN 1957/4885RAB9A 2711/4885LMNA 2507/4885 |
| US-20100041634-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | ZYX, NQO2, PYCR1 | FASN 1957/4885RAB9A 2711/4885LMNA 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.